Table 4 Analyses for the association between survival outcomes and clinical characteristics.
Variables | Progression-free survival | ||
|---|---|---|---|
Unadjusted hazard ratio | 95% Confidence interval | P value | |
Sex (female vs male) | 1.34 | 0.67–2.68 | 0.41 |
Age (≥ vs <60 years) | 0.80 | 0.41–1.57 | 0.52 |
Baseline serum CA 19-9 levels (elevated vs within normal range) | 1.18 | 0.68–1.18 | 0.68 |
Primary tumour site (head vs body/tail) | 0.44 | 0.22–0.90 | 0.02 |
Response to mFOLFIRINOX (CR/PR vs SD/PD) | 0.54 | 0.26–1.12 | 0.09 |
Disease extent by central review (LAUPC vs BRPC) | 1.00 | 0.41–2.43 | 1.00 |
Conversion surgery (yes vs no) | 0.23 | 0.11–0.47 | <0.001 |
Variables | Overall survival | ||
Sex (female vs male) | 1.52 | 0.65–3.55 | 0.34 |
Age (≥ vs <60 years) | 0.67 | 0.28–1.60 | 0.37 |
Baseline serum CA 19-9 levels (elevated vs within normal range) | 0.68 | 0.28–1.67 | 0.40 |
Primary tumour site (head vs body/tail) | 0.36 | 0.15–0.85 | 0.02 |
Response to mFOLFIRINOX (CR/PR vs SD/PD) | 0.37 | 0.14–1.02 | 0.046 |
Disease extent by central review (LAUPC vs BRPC) | 1.25 | 0.46–3.39 | 0.66 |
Conversion surgery (yes vs no) | 0.14 | 0.05–0.39 | <0.001 |
